Advances in Hyperkalemia Management: Implications for Patients and Providers

Advances in Hyperkalemia Management: Implications for Patients and Providers is organized by Rockpointe Corporation.

Release date: September 30, 2019 
Experiation date: September 30, 2020

Accreditation:
Designation Statement?
MedChi designates this online web-based activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

ABIM MOC Designation:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Overview:
Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use (specifically with sodium polystyrene sulfonate). For medication-induced hyperkalemia, treatment involves a dose decrease or discontinuation of the offending agent (usually a renin-angiotensin-aldosterone system inhibitor [RAASI]); however, this often prevents patients from receiving appropriate guideline-directed management. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.

This CME activity, Advances in Hyperkalemia Management: Implications for Patients and Providers, will help participating clinicians identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.

Educational Objectives:
At the conclusion of this activity, participants should be able to:
• Compare and contrast safety and efficacy data on novel and conventional agents for correcting subacute/chronic hyperkalemia
• Identify patient populations likely to present with or develop hyperkalemia
• Incorporate novel agents for correcting subacute hyperkalemia into patient care plans